| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Therapy: Preclinical |
Authors' Affiliations: 1 Galaxy Biotech, LLC, Mountain View, California; 2 Division of Neurosurgery, University of Alabama at Birmingham, Birmingham, Alabama; and 3 Department of Neurology, The Kennedy Krieger Research Institute and The Johns Hopkins University School of Medicine, Baltimore, Maryland
Requests for reprints: K. Jin Kim, Galaxy Biotech, LLC, 2462 Wyandotte Street, Mountain View, CA 94033. Phone: 650-964-4966, ext. 214; Fax: 650-694-7717; E-mail: kjinkim{at}msn.com.
Purpose: Hepatocyte growth factor (HGF) and its receptor Met are involved in the initiation, progression, and metastasis of numerous systemic and central nervous system tumors. Thus, an anti-HGF monoclonal antibody (mAb) capable of blocking the HGF-Met interaction could have broad applicability in cancer therapy.
Experimental Design: An anti-HGF mAb L2G7 that blocks binding of HGF to Met was generated by hybridoma technology, and its ability to inhibit the various biological activities of HGF was measured by in vitro assays. The ability of L2G7 to inhibit the growth of tumors was determined by establishing s.c. and intracranial xenografts of human U87 and U118 glioma cell lines in nude mice, and treatment with 100 µg of L2G7 or control given i.p. twice per week.
Results: MAb L2G7 strongly inhibited all biological activities of HGF measured in vitro, including cell proliferation, cell scattering, and endothelial tubule formation. Treatment with L2G7 completely inhibited the growth of established s.c. xenografts in nude mice. Moreover, systemic administration of L2G7 from day 5 induced the regression of intracranial U87 xenografts and dramatically prolonged the survival of tumor-bearing mice from a median of 39 to >90 days. L2G7 treatment of large intracranial tumors (average tumor size, 26.7 mm3) from day 18 induced substantial tumor regression (control group, 134.3 mm3; L2G7 treated group, 11.7 mm3) by day 29 and again prolonged animal survival.
Conclusions: These findings show that blocking the HGF-Met interaction with systemically given anti-HGF mAb can have profound antitumor effects even within the central nervous system, a site previously believed to be resistant to systemic antibody-based therapeutics.
This article has been cited by other articles:
|
|
 |
|
  S. Nimmagadda, M. Pullambhatla, and M. G. Pomper Immunoimaging of CXCR4 Expression in Brain Tumor Xenografts Using SPECT/CT J. Nucl. Med., July 1, 2009; 50(7): 1124 - 1130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Li, F. Guessous, C. DiPierro, Y. Zhang, T. Mudrick, L. Fuller, E. Johnson, L. Marcinkiewicz, M. Engelhardt, B. Kefas, et al. Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy Mol. Cancer Ther., February 1, 2009; 8(2): 376 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Vigna, G. Pacchiana, M. Mazzone, C. Chiriaco, L. Fontani, C. Basilico, S. Pennacchietti, and P. M. Comoglio "Active" Cancer Immunotherapy by Anti-Met Antibody Gene Transfer Cancer Res., November 15, 2008; 68(22): 9176 - 9183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Binning, T. Niazi, C. A. Pedone, B. Lal, C. G. Eberhart, K. J. Kim, J. Laterra, and D. W. Fults Hepatocyte Growth Factor and Sonic Hedgehog Expression in Cerebellar Neural Progenitor Cells Costimulate Medulloblastoma Initiation and Growth Cancer Res., October 1, 2008; 68(19): 7838 - 7845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Toschi and P. A. Janne Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer Clin. Cancer Res., October 1, 2008; 14(19): 5941 - 5946. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Idbaih, F. Ducray, M. Sierra Del Rio, K. Hoang-Xuan, and J.-Y. Delattre Therapeutic Application of Noncytotoxic Molecular Targeted Therapy in Gliomas: Growth Factor Receptors and Angiogenesis Inhibitors Oncologist, September 1, 2008; 13(9): 978 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Basilico, A. Arnesano, M. Galluzzo, P. M. Comoglio, and P. Michieli A High Affinity Hepatocyte Growth Factor-binding Site in the Immunoglobulin-like Region of Met J. Biol. Chem., July 25, 2008; 283(30): 21267 - 21277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Tiran, A. Oren, C. Hermesh, G. Rotman, Z. Levine, H. Amitai, T. Handelsman, M. Beiman, A. Chen, D. Landesman-Milo, et al. A Novel Recombinant Soluble Splice Variant of Met Is a Potent Antagonist of the Hepatocyte Growth Factor/Scatter Factor-Met Pathway Clin. Cancer Res., July 15, 2008; 14(14): 4612 - 4621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. P. Stabile, M. E. Rothstein, P. Keohavong, J. Jin, J. Yin, S. R. Land, S. Dacic, T. M. Luong, K. J. Kim, A. M. Dulak, et al. Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis Mol. Cancer Ther., July 1, 2008; 7(7): 1913 - 1922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kim, U. J. Lee, M. N. Kim, E.-J. Lee, J. Y. Kim, M. Y. Lee, S. Choung, Y. J. Kim, and Y.-C. Choi MicroRNA miR-199a* Regulates the MET Proto-oncogene and the Downstream Extracellular Signal-regulated Kinase 2 (ERK2) J. Biol. Chem., June 27, 2008; 283(26): 18158 - 18166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ginty, S. Adak, A. Can, M. Gerdes, M. Larsen, H. Cline, R. Filkins, Z. Pang, Q. Li, and M. C. Montalto The Relative Distribution of Membranous and Cytoplasmic Met Is a Prognostic Indicator in Stage I and II Colon Cancer Clin. Cancer Res., June 15, 2008; 14(12): 3814 - 3822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Jin, R. Yang, Z. Zheng, M. Romero, J. Ross, H. Bou-Reslan, R. A.D. Carano, I. Kasman, E. Mai, J. Young, et al. MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival Cancer Res., June 1, 2008; 68(11): 4360 - 4368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. Bellon, P. Kaplan-Lefko, Y. Yang, Y. Zhang, J. Moriguchi, K. Rex, C. W. Johnson, P. E. Rose, A. M. Long, A. B. O'Connor, et al. c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related Mutations J. Biol. Chem., February 1, 2008; 283(5): 2675 - 2683. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Reznik, Y. Sang, Y. Ma, R. Abounader, E. M. Rosen, S. Xia, and J. Laterra Transcription-Dependent Epidermal Growth Factor Receptor Activation by Hepatocyte Growth Factor Mol. Cancer Res., January 1, 2008; 6(1): 139 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. T. Jun, J. Sun, K. Rex, R. Radinsky, R. Kendall, A. Coxon, and T. L. Burgess AMG 102, A Fully Human Anti-Hepatocyte Growth Factor/Scatter Factor Neutralizing Antibody, Enhances the Efficacy of Temozolomide or Docetaxel in U-87 MG Cells and Xenografts Clin. Cancer Res., November 15, 2007; 13(22): 6735 - 6742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Siegfried, C. T. Gubish, M. E. Rothstein, P. E. Q. de Oliveira, and L. P. Stabile Signaling Pathways Involved in Cyclooxygenase-2 Induction by Hepatocyte Growth Factor in Non Small-Cell Lung Cancer Mol. Pharmacol., September 1, 2007; 72(3): 769 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Myerburg, J. D. Latoche, E. E. McKenna, L. P. Stabile, J. S. Siegfried, C. A. Feghali-Bostwick, and J. M. Pilewski Hepatocyte growth factor and other fibroblast secretions modulate the phenotype of human bronchial epithelial cells Am J Physiol Lung Cell Mol Physiol, June 1, 2007; 292(6): L1352 - L1360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R.J. Carlson, W. B. Pope, S. Horvath, J. G. Braunstein, P. Nghiemphu, C.-L. Tso, I. Mellinghoff, A. Lai, L. M. Liau, P. S. Mischel, et al. Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2 Clin. Cancer Res., May 1, 2007; 13(9): 2592 - 2598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bardella, D. Dettori, M. Olivero, N. Coltella, M. Mazzone, and M. F. Di Renzo The Therapeutic Potential of Hepatocyte Growth Factor to Sensitize Ovarian Cancer Cells to Cisplatin and Paclitaxel In vivo Clin. Cancer Res., April 1, 2007; 13(7): 2191 - 2198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Linehan, P. A. Pinto, R. Srinivasan, M. Merino, P. Choyke, L. Choyke, J. Coleman, J. Toro, G. Glenn, C. Vocke, et al. Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics Clin. Cancer Res., January 15, 2007; 13(2): 671s - 679s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Martens, N.-O. Schmidt, C. Eckerich, R. Fillbrandt, M. Merchant, R. Schwall, M. Westphal, and K. Lamszus A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo. Clin. Cancer Res., October 15, 2006; 12(20): 6144 - 6152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. P. Stabile, J. S. Lyker, S. R. Land, S. Dacic, B. A. Zamboni, and J. M. Siegfried Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer Carcinogenesis, August 1, 2006; 27(8): 1547 - 1555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Peruzzi and D. P. Bottaro Targeting the c-Met Signaling Pathway in Cancer. Clin. Cancer Res., June 15, 2006; 12(12): 3657 - 3660. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
